This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Linsley, P S Articles by Neubauer, M Search for Related Content PubMed PubMed Citation Articles by Linsley, P S Articles by Neubauer, M

 Previous Article  |  Next Article 

Mol Cell Biol. 1990 May; 10(5): 1882-1890

Cleavage of a hydrophilic C-terminal domain increases growth-inhibitory activity of oncostatin M.

Oncogen, Seattle, Washington 98121.

ABSTRACT

Oncostatin M is a polypeptide cytokine, produced by normal and malignant hematopoietic cells, that has several in vitro activities, including the ability to inhibit growth of cultured carcinoma cells. Here we present a structural and functional comparison of two oncostatin M-related proteins (Mr 36,000 and 32,000) secreted by COS cells transfected with oncostatin M cDNA. The smaller of these forms lacked a hydrophilic C-terminal domain comprising predominantly basic amino acids. This domain was also absent from native oncostatin M produced by U937 cells. The 32,000-Mr form of oncostatin M was not produced by cells transfected with plasmids (G195 and G196) in which a potential trypsinlike cleavage site within the hydrophilic C-terminal domain was altered by site-directed mutagenesis. A 32,000-Mr fragment was produced by trypsin treatment of the 36,000-Mr form of oncostatin M. These observations suggest that the 32,000-Mr form of oncostatin M was derived from the 227-amino-acid propeptide by proteolytic cleavage at or near the paired basic residues at positions 195 and 196. Pro-oncostatin M was equally active in radioreceptor assays as the processed form but was 5- to 60-fold less active in growth inhibition assays. Likewise, nonprocessed mutant protein encoded by plasmid G196 was equally active in the radioreceptor assays as the processed form but was five- to ninefold less active in growth inhibition assays. Thus, the highly charged C-terminal domain of pro-oncostatin M is not required for receptor binding or growth-inhibitory activity but may alter the functional properties of the molecule. Propeptide processing of oncostatin M may be important for regulating in vivo activities of this cytokine.

This article has been cited by other articles:

• Huising, M. O, Kruiswijk, C. P, Flik, G. (2006). Phylogeny and evolution of class-I helical cytokines.. J Endocrinol 189: 1-25 [Abstract] [Full Text]  
• Ohata, Y., Harada, T., Fujii, A., Yoshida, S., Iwabe, T., Terakawa, N. (2001). Menstrual cycle-specific inhibition of endometrial stromal cell proliferation by oncostatin M. Mol Hum Reprod 7: 665-670 [Abstract] [Full Text]  
• Nakayama, K., Hara, T., Hibi, M., Hirano, T., Miyajima, A. (1999). A Novel Oncostatin M-inducible Gene OIG37 Forms a Gene Family with MyD118 and GADD45 and Negatively Regulates Cell Growth. J. Biol. Chem. 274: 24766-24772 [Abstract] [Full Text]  
• Ichihara, M., Hara, T., Kim, H., Murate, T., Miyajima, A. (1997). Oncostatin M and Leukemia Inhibitory Factor Do Not Use the Same Functional Receptor in Mice. Blood 90: 165-173 [Abstract] [Full Text]  
• Miles, S., Martinez-Maza, O, Rezai, A, Magpantay, L, Kishimoto, T, Nakamura, S, Radka, S., Linsley, P. (1992). Oncostatin M as a potent mitogen for AIDS-Kaposi's sarcoma-derived cells. Science 255: 1432-1434 [Abstract]